Industry Outlook and Trend Analysis
The Rare Neurological Disease Treatment Market was worth USD 4.82 billion in 2014 and is expected to reach approximately USD 10.16 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 8.63% during the forecast period. Larger part of rare diseases currently have none or minimal viable techniques of diagnosis & treatment, which can be partially credited to lack of subsidizing toward researches about on rare disease pathogenesis and lack of representative patients. Rare neurological diseases are among the main types of rare diseases with insufficient diagnoses and treatment alternatives. Brain diseases are thought to be one of the main determinants of the neurological disease predominance globally, with early diagnosis being the main key to avert or shorten long-term morbidity and applicable healthcare costs. Spreading awareness regarding these diseases alongside expanding their visibility is key activities taken by different governments worldwide for accelerating diagnostic procedures and provides affected families with access to appropriate advising and treatment choices.
Indication Outlook and Trend Analysis
On the basis of indication Alzhiemer's disease is foreseen to continue dominating the market over the forecast period. Furthermore, revenues from treatment of this indication portion are probably going to record the speediest ascent in the market throughout the forecast period.
Drug Type Outlook and Trend Analysis
Biologics will keep on being the favoured drug for treatment of rare neurological diseases. Revenues from sales of biologics will represent the lion's share of the market through the conjecture time frame, in terms of drug type.
Mode of Administration Outlook and Trend Analysis
Based on mode of administration the market is segmented into injectable and orals. Injectable will continue to rule the market for treating rare neurological conditions.
Distribution Channel Outlook and Trend Analysis
On the basis of distribution channel the market is segmented into online pharmacies, retail pharmacies and hospital pharmacies. Governments over the globe are making huge enhancements in their healthcare systems to render their administration to be holistic, multidisciplinary, and to incorporate steady and palliative care.
Regional Outlook and Trend Analysis
In North America, rare neurological conditions are thought to be a serious healthcare concern, although few individuals are presently influenced by the disease. Complications of these diseases, along with their insufficiency in treatment choices have prompted disproportionate share of spending in healthcare.
The leading players in the market are Johnson & Johnson, Medtronic Plc, Teva Pharmaceutical Industries Limited, Novartis AG, Bayer Aktiengesellschaft, Pfizer Inc and Allergan Plc. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
The Rare Neurological Disease Treatment Market is segmented as follows-
Amyotrophic Lateral Sclerosis
By Drug Type:
By Mode of Administration:
By Distribution Channel:
Rest of Europe
Rest of Asia-Pacific
Rest of South America
Middle East and Africa
Rest of MEA
Some of the key questions answered by the report are:
What was the market size in 2014 and forecast from 2015 to 2023?
What will be the industry market growth from 2015 to 2023?
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
What are the major segments leading the market growth and why?
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?